Michael Nash

Committed biomedical professional with a proven track record in designing and implementing in vitro assays to assess the efficacy of advanced therapeutics. In a highly collaborative work environment, having excelled as a member of integrated project teams. My role has involved analyzing complex data and transforming it into clear, accessible formats. Additionally, have actively contribute to team discussions and initiate new project initiatives, driving progress and facilitating the achievement of long-term goals. I am eager to apply my expertise and collaborative spirit to contribute meaningfully to innovative projects within a dynamic and forward-thinking organization.

JE Mortimer, CC Bamdad, Y Yuan, JM Specht, AK Stewart, BJ Smagghe, SC Lin, MG
Carter, TW Synold, MD Fleming, SR Hamilton, V Parekh, DM Walkley, Q
Liu-Michael, KR Yi, JSS Nash, MJ Nash, SJ Forman.. 1st-in-human CAR T targets
MUC1 transmembrane cleavage product. In: San Antonio Breast Cancer
Symposium; 2023 December 5-9; An Antonio, Texas. San Antonio (TX): SABCS;
2023. Poster PO5-19-03.